What do drugmakers think about RFK Jr.? Why has it been so hard to bring gene therapies to market? And what tacos did Adam have this week while attending the American Society of Hematology conference?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Washington correspondent John Wilkerson joins us to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.’s nomination to lead the Department of Health and Human Services, despite his repeated criticisms of the pharmaceutical industry.
We also bring on our colleague Jason Mast to talk about the major hurdles in the field of gene therapy and how one father is trying to overcome them.
For more on the pharma industry’s silence on RFK Jr.’s nomination, go here; to read more about one father’s efforts to develop gene therapies for rare diseases, go here; for more of STAT’s coverage of the ASH conference, go here; and to learn more about Eli Lilly’s plans to study obesity drugs in addiction, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts.